The study achieved its primary endpoint — treatment with the drug ... Pfizer this year in the hemophilia space. Earlier in July, the FDA approved Durveqtix (fidanacogene elaparvovec), the ...

Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...

making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel. US FDA approves BridgeBio's drug for rare heart condition (Nov 22) November 25, 2024 A trial ended with a ...

The FDA has approved Rapiblyk ... Rapiblyk, the brand name for landiolol, is an injectable drug that slows the heart rate by blocking adrenaline's action on beta-1 receptors in the heart.

1 Diagnosed in early childhood, hemophilia inhibits the blood’s ... the FDA at 1-800-FDA-1088. Disclosure notice The information contained in this release is as of November 20, 2024. Pfizer ...

FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC trial. Imfinzi shows median overall survival of 55.9 months versus ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...